Ten EMA initiatives will strengthen clinical research in Europe

The framework conditions for clinical research in Europe have proved challenging and difficult, the EMA says. With ten new initiatives, the European health authority wants to change how trials are designed, initiated and conducted. Industry association Lif welcomes the changes.

With ten new initiatives, the European health authority wants to strenghten clinical research in Europe | Photo: Bioneer / PR

by ALBERT RØNNING-ANDERSSON, translated by daniel pedersen

Published: 14.01.22 at 15:41

Clinical trials are a necessity for the development of drugs, medical equipment, new treatments and the life science industry at large.

Yet, as things are today, it has become difficult for European pharmaceutical, medtech and biotech companies to apply for clinical trial authorization, according to the European Medicines Agency (EMA). Ten new initiatives from the health authority will change the way studies are designed, initiated and conducted.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

Access all locked articles
Receive our daily newsletters
Access our app

Start a free company trial today

More from MedWatch

Bavarian Nordic ramps up monkeypox vaccine production

Paul Chaplin, CEO of Bavarian Nordic | Photo: Bavarian Nordic /PR

CEO Paul Chaplin reports that Bavarian is making more doses of its vaccine against monkeypox due to the recent outbreak.

Carb-X secures USD 370m in fight against antibiotic resistance

Aleks Engel, a partner of Novo Holdings’s antimicrobial activities, the Repair Impact Fund | Foto: Novo Holdings / PR

International antibiotic alliance Carb-X has received commitments of up to USD 370m to accelerate the development of new antibiotics to combat a future shortage. The news is welcomed by several players on the AMR field.

Former Ambu CEO's equity investments end in USD 2m losses

Juan Jose Gonzalez, who was the CEO of medtech firm Ambu until very recently, has lost just over DKK 16m (USD 2.3m) before taxes on his share purchases.

Jesper Høiland retires as chief commercial officer of Ascendis Pharma

Jesper Høiland, outgoing global chief commercial officer of Ascendis Pharma | Foto: Radius Health / PR

Former executive vice president of Novo Nordisk, US, Jesper Høiland has decided to step down from his role as global chief commercial officer at Ascendis Pharma.

ALK finds replacement for long-time North America lead

Nearly 23 years as head of the US at ALK have come to end for Jorge Alderete, who is retiring effective June 30 | Foto: ALK / PR

Jorge Alderete, ALK’s president in North America, is leaving the firm after 23 years. He will be replaced by Hans Lindeberg, ALK’s current head of the Nordic region.

Further reading

Related articles